Methods of manufacture of nut flours and/or formulations, ultra-low fat nut flours and uses for nut flour formulations. In some embodiments, methods of manufacturing ultra-low fat tree nut or peanut flour formulations for oral administration in immunotherapy of subjects affected by allergies.

A method for delivering an immunomodulator to a patient includes providing a bottle of concentrated immunomodulator extract; progressively diluting the antigen extract in sterile bottles; selecting a prescribed amount from a desired one of the dilution bottles; providing a viscous encapsulation material that is able to introduce antigens contained therein through the skin of a patient; introducing one or more doses of the selected prescribed amount of diluted immunomodulator into the viscous encapsulation material; disposing a prescribed amount of viscous encapsulation material containing the introduced diluted immunomodulator therein within a container that is able to dispense such viscous encapsulation material containing the introduced diluted immunomodulator; dispensing from the container the amount of viscous encapsulation material containing the diluted immunomodulator in an amount equal to a single dose; and applying the dispensed viscous encapsulation material containing the introduced diluted immunomodulator to the skin by the patient or a medical professional.

A method for delivering an immunomodulator to a patient includes providing a bottle of concentrated immunomodulator extract; progressively diluting the antigen extract in sterile bottles; selecting a prescribed amount from a desired one of the dilution bottles; providing a viscous encapsulation material that is able to introduce antigens contained therein through the skin of a patient; introducing one or more doses of the selected prescribed amount of diluted immunomodulator into the viscous encapsulation material; disposing a prescribed amount of viscous encapsulation material containing the introduced diluted immunomodulator therein within a container that is able to dispense such viscous encapsulation material containing the introduced diluted immunomodulator; dispensing from the container the amount of viscous encapsulation material containing the diluted immunomodulator in an amount equal to a single dose; and applying the dispensed viscous encapsulation material containing the introduced diluted immunomodulator to the skin by the patient or a medical professional.

The present invention relates to a nutritional composition comprising non-denatured lactoferrin for use in preventing or treating allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler.

The present invention relates to a nutritional composition comprising non-denatured lactoferrin for use in preventing or treating allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler.

Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

The present invention relates to the asthma-protective effects of farm dust, specifically to a composition comprising barn dust extract including isolated fractions of an Amish barn dust extract comprising different bioactive components that have an ability to protect against asthma. In particular, the present invention describes a barn dust composition with asthma-protective properties, the barn dust composition comprising one or more bioactive fractions extracted from barn dust, said one or more bioactive fractions comprising one or more proteins and one or more fatty acids. The one or more bioactive fractions of the barn dust compositions may comprise molecular weights of 30-100 kDa, particularly 28-64 kDA, that include eight (8) target proteins, which have potential to proactively prevent the induction of asthma and to treat current cases of asthma. The present invention also relates to an in vitro method for screening allergic compounds.

The present invention relates to the asthma-protective effects of farm dust, specifically to a composition comprising barn dust extract including isolated fractions of an Amish barn dust extract comprising different bioactive components that have an ability to protect against asthma. In particular, the present invention describes a barn dust composition with asthma-protective properties, the barn dust composition comprising one or more bioactive fractions extracted from barn dust, said one or more bioactive fractions comprising one or more proteins and one or more fatty acids. The one or more bioactive fractions of the barn dust compositions may comprise molecular weights of 30-100 kDa, particularly 28-64 kDA, that include eight (8) target proteins, which have potential to proactively prevent the induction of asthma and to treat current cases of asthma. The present invention also relates to an in vitro method for screening allergic compounds.

The present invention provides highly effective and safe means capable of preventing or treating an egg allergy in infants. An oral immunotolerance agent or a food composition for preventing or treating an egg allergy according to the present invention contains a degraded product of heat-denatured egg white with an aspartic protease (e.g. pepsin) or a metal protease (e.g. thermolysin).